Vasopressin antagonists in acute heart failure syndromes

Cesare Orlandi, Filippo Brandimarte, Mihai Gheorghiade

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The contribution of neurohormonal abnormalities in the pathophysiology of chronic heart failure (CHF) is well established. Attenuation of the excessive and continuous activation of angiotensin II and β-adrenergic receptors in patients with CHF with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, respectively, has resulted in substantial reductions in morbidity and mortality. However, it is not clear whether intervention with other neuroendocrine modulators (e.g., tumor necrosis factor [TNF] or endothelin) could result in similar benefits.

Original languageEnglish (US)
Title of host publicationAcute Heart Failure
PublisherSpringer London
Pages621-625
Number of pages5
ISBN (Print)9781846287817
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Vasopressin antagonists in acute heart failure syndromes'. Together they form a unique fingerprint.

  • Cite this

    Orlandi, C., Brandimarte, F., & Gheorghiade, M. (2008). Vasopressin antagonists in acute heart failure syndromes. In Acute Heart Failure (pp. 621-625). Springer London. https://doi.org/10.1007/978-1-84628-782-4_57